Literature DB >> 31749390

The Influence of Murine Genetic Background in Adeno-Associated Virus Transduction of the Mouse Brain.

Ting He1, Michelle S Itano2,3, Lauriel F Earley1, Nikita E Hall1, Natallia Riddick3, R Jude Samulski1,4, Chengwen Li1,3,5.   

Abstract

Adeno-associated virus (AAV) vectors have become an important tool for delivering therapeutic genes for a wide range of neurological diseases. AAV serotypes possess differential cellular tropism in the central nervous system. Although several AAV serotypes or mutants have been reported to transduce the brain efficiently, conflicting data occur across studies with the use of various rodent strains from different genetic backgrounds. Herein, we performed a systematic comparison of the brain transduction properties among five AAV serotypes (AAV2, 5, 7, 8, and 9) in two common rodent strains (C57BL/6J and FVB/N), following local intrastriatal injection of AAV vectors encoding enhanced green fluorescent protein (EGFP) driven by the CBh promoter. Important differences were found regarding overall cellular tropism and transduction efficiency, including contralateral transduction among the AAV serotypes and between the mouse strains. We have further found loss of NeuN-immunoreactivity and microglial activation from AAV transduction in the different mouse strains. The important strain-specific differences from our study suggest that the genetic background of the mouse may affect AAV serotype transduction properties in the brain. These data can provide valuable information about how to choose an effective AAV vector for clinical application and interpret the data obtained from preclinical studies and clinical trials.

Entities:  

Keywords:  AAV; NeuN; brain transduction; mouse strains; serotypes

Mesh:

Substances:

Year:  2019        PMID: 31749390      PMCID: PMC6919261          DOI: 10.1089/humc.2019.030

Source DB:  PubMed          Journal:  Hum Gene Ther Clin Dev        ISSN: 2324-8637            Impact factor:   5.032


  44 in total

1.  The molecular basis of the specificity and cross-reactivity of the NeuN epitope of the neuron-specific splicing regulator, Rbfox3.

Authors:  Stephan Maxeiner; Alexander Glassmann; Hung-Teh Kao; Karl Schilling
Journal:  Histochem Cell Biol       Date:  2013-10-23       Impact factor: 4.304

2.  Characterization of the neuronal marker NeuN as a multiply phosphorylated antigen with discrete subcellular localization.

Authors:  Daniela Lind; Sebastian Franken; Joachim Kappler; Jakob Jankowski; Karl Schilling
Journal:  J Neurosci Res       Date:  2005-02-01       Impact factor: 4.164

3.  FVB/N: an inbred mouse strain preferable for transgenic analyses.

Authors:  M Taketo; A C Schroeder; L E Mobraaten; K B Gunning; G Hanten; R R Fox; T H Roderick; C L Stewart; F Lilly; C T Hansen
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

4.  Axotomy abolishes NeuN expression in facial but not rubrospinal neurons.

Authors:  Lowell T McPhail; Christopher B McBride; John McGraw; John D Steeves; Wolfram Tetzlaff
Journal:  Exp Neurol       Date:  2004-01       Impact factor: 5.330

Review 5.  Is bipolar disorder an inflammatory condition? The relevance of microglial activation.

Authors:  Laura Stertz; Pedro V S Magalhães; Flávio Kapczinski
Journal:  Curr Opin Psychiatry       Date:  2013-01       Impact factor: 4.741

6.  Conditional targeting of medium spiny neurons in the striatal matrix.

Authors:  Björn Reinius; Martina Blunder; Frances M Brett; Anders Eriksson; Kalicharan Patra; Jörgen Jonsson; Elena Jazin; Klas Kullander
Journal:  Front Behav Neurosci       Date:  2015-03-27       Impact factor: 3.558

7.  Analysis of transduction efficiency, tropism and axonal transport of AAV serotypes 1, 2, 5, 6, 8 and 9 in the mouse brain.

Authors:  Dominik F Aschauer; Sebastian Kreuz; Simon Rumpel
Journal:  PLoS One       Date:  2013-09-27       Impact factor: 3.240

Review 8.  Adeno-Associated Virus-Based Gene Therapy for CNS Diseases.

Authors:  Michaël Hocquemiller; Laura Giersch; Mickael Audrain; Samantha Parker; Nathalie Cartier
Journal:  Hum Gene Ther       Date:  2016-07       Impact factor: 5.695

9.  An essential receptor for adeno-associated virus infection.

Authors:  S Pillay; N L Meyer; A S Puschnik; O Davulcu; J Diep; Y Ishikawa; L T Jae; J E Wosen; C M Nagamine; M S Chapman; J E Carette
Journal:  Nature       Date:  2016-01-27       Impact factor: 49.962

Review 10.  Gene Therapy for Parkinson's Disease, An Update.

Authors:  Tobias M Axelsen; David P D Woldbye
Journal:  J Parkinsons Dis       Date:  2018       Impact factor: 5.568

View more
  5 in total

1.  Customized blood-brain barrier shuttle peptide to increase AAV9 vector crossing the BBB and augment transduction in the brain.

Authors:  Xintao Zhang; Zheng Chai; Amanda Lee Dobbins; Michelle S Itano; Charles Askew; Zhe Miao; Hongqian Niu; R Jude Samulski; Chengwen Li
Journal:  Biomaterials       Date:  2021-12-31       Impact factor: 12.479

Review 2.  Viral tools for neuroscience.

Authors:  Alexander R Nectow; Eric J Nestler
Journal:  Nat Rev Neurosci       Date:  2020-10-27       Impact factor: 34.870

3.  Mitochondrial targeted meganuclease as a platform to eliminate mutant mtDNA in vivo.

Authors:  Ugne Zekonyte; Sandra R Bacman; Jeff Smith; Wendy Shoop; Claudia V Pereira; Ginger Tomberlin; James Stewart; Derek Jantz; Carlos T Moraes
Journal:  Nat Commun       Date:  2021-05-28       Impact factor: 14.919

Review 4.  AAV Targeting of Glial Cell Types in the Central and Peripheral Nervous System and Relevance to Human Gene Therapy.

Authors:  Simon J O'Carroll; William H Cook; Deborah Young
Journal:  Front Mol Neurosci       Date:  2021-01-11       Impact factor: 5.639

5.  Intramuscular Delivery of Gene Therapy for Targeting the Nervous System.

Authors:  Andrew P Tosolini; James N Sleigh
Journal:  Front Mol Neurosci       Date:  2020-07-17       Impact factor: 5.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.